MétaCan
Menu
← Retour à la cohorte
Enregistrement W2413543718 · doi:10.1182/blood.v122.21.5407.5407

In Vitro Stromal Co-Culture Model For The Evaluation Of Reovirus Oncolytic Therapy For Refractory Pediatric Leukemia

2013· article· en· W2413543718 sur OpenAlexaff
Gaya Narendran, Matthew Clarkson, Randal N. Johnston

Notice bibliographique

RevueBlood · 2013
Typearticle
Langueen
DomaineBiochemistry, Genetics and Molecular Biology
ThématiqueVirus-based gene therapy research
Établissements canadiensUniversity of Calgary
Organismes subventionnairesnon disponible
Mots-clésMedicineStromal cellLeukemiaCancer researchBone marrowOncolytic virusImmunologyMyeloid leukemiaPlerixaforContext (archaeology)Tumor microenvironmentOncologyCancerCXCR4Internal medicineBiologyChemokineImmune system

Résumé

récupéré en direct d'OpenAlex

Abstract Introduction Acute lymphoblastic leukemia (ALL) is the most common malignant disease in children, constituting more than a quarter of all childhood cancers. The survival rate of standard/good risk ALL now exceeds 80%. In spite of the significant improvements in outcome, the emergence of resistant disease remains the most common cause of death. Escalation of the intensity of combination chemotherapy with the introduction of second-line drugs is accompanied by cumulative toxicity, with marginal incremental benefits. Hence novel therapeutic approaches are urgently needed to improve the outcome in these patients. In addition to the inherent molecular alterations, recent reports have suggested an active role for the bone marrow stromal microenvironment in promoting both leukemia cell viability and drug resistance. Previous studies have shown a pivotal role for the stromal chemokine CXCL12 (SDF-1) and its receptor CXCR4 in this process. In the multiple myeloma model, inhibition of CXCR4 by the targeted agent AMD3100 (Plerixafor) abrogates the chemotherapy protection conferred by stromal cells. Recent years have seen evidence for the effectiveness of oncolytic viruses as cytotoxic agents against refractory tumors. The strategy behind this approach is to develop viruses that can replicate and cause cell lysis specifically in cancer cells while leaving non-malignant cells unaffected. In this study we explore the utility of reovirus mediated anti-leukemic therapy in an experimental model of pediatric leukemia in the context of co-culture with bone marrow stromal cells. Methods A panel of leukemia cell lines (n=4) representing pediatric ALL and acute myeloid leukemia (AML) were evaluated when co-cultured in the presence of stromal conditioned medium, live bone marrow stromal cells, stromal cells fixed with 0.5% glutaraldehyde, or control human skin fibroblasts (1Br3 cells). After three days in culture, cell proliferation kinetics under each condition was measured by WST-1 assay. The influence of nonspecific leukemia cell attachment was evaluated by the culture of leukemia cells in poly-L-lysine coated plates. Next the leukemic cells were treated with oncolytic reovirus, at various concentrations with and without co-cultures conditions to evaluate the potential of leukemia cells to escape reovirus mediated cytolysis. Finally, the ability of stromal cells to modulate reovirus anti-leukemic activity was evaluated in the presence of various concentrations of AMD3100. Results and Discussion An average of a 2-fold increase in leukemia cell proliferation (in the absence of reovirus) was seen with live stromal co-cultures compared to conditioned media or fixed stromal cells, indicating the requirement of live cell-cell contact with stromal cells in this process. Poly-L lysine coated plates did not increase leukemia cell growth. Our data reveals that, as previously seen with chemotherapeutic drug exposure, the presence of stromal cells is able to decrease the cytolytic activity of reovirus on leukemic cells. Leukemia cells alone exhibit a survival of 10% following a three-day exposure to reovirus (50 MOI). However, in the presence of stromal the survival rate was increased to 40% (p < 0.05). Furthermore, the addition of AMD3100 provided partial restoration of the oncolytic activity (mean 15% survival, n=3 experiments). Stromal conditioned media also decreased reovirus infectivity, although to a lower extent (mean 17% cell survival). Co-culture of leukemia cells with control 1br3 human skin fibroblast cells provided no protection from reoviral cytolysis (mean 10% survival). In this proof-of-concept study, we provide evidence for the first time that the bone marrow niche may provide at least partial protection from oncolytic virotherapy. This indicates the importance of evaluating the efficacy of oncolytic viruses in the context of the tumor microenvironment in future studies. Furthermore, we provide evidence for the consideration of combination therapies with targeted agents such as AMD3100, which may disrupt the stromal protective activities, to increase the effectiveness virotherapy in the treatment of refractory leukemia. Disclosures: No relevant conflicts of interest to declare.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Expérimental (laboratoire) · Signal consensuel: Expérimental (laboratoire)
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,002
Score d'incertitude au seuil0,006

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,001
Charge utile insuffisante (le modèle a refusé de juger)0,0020,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,043
Tête enseignante GPT0,353
Écart entre enseignants0,309 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeExpérimental (laboratoire)
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2013
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueBlood→Même sujetVirus-based gene therapy research→Travaux en français237 207→